
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc has successfully closed a $57.5 million public offering, which significantly bolsters its financial resources to support ongoing antibody development programs. The company’s focus on innovative antibody solutions for viral diseases, particularly its candidates ADG20 and VYD222, positions it to excel in addressing pandemic threats, thereby enhancing its growth potential in a rapidly evolving market. Furthermore, the shift in valuation metrics forward from year-end 2025 to year-end 2026 reflects a positive trend, contributing to an optimistic long-term financial outlook for Invivyd.
Bears say
Invivyd Inc. has experienced a downward revision in expectations concerning its market share for PEMGARDA among immunocompromised patients, indicating a potential challenge in achieving projected revenue targets in this segment. Additionally, a significant dilution from a capital raise has prompted a reduction in the price target from $3.00 to $1.00, reflecting concerns over investor value and future earnings potential. These factors contribute to a negative outlook for the company's stock, as they suggest weakening market dynamics and potential financial instability.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares